Shield Therapeutics has raised funds

Shield Therapeutics Plc has completed a placing, subscription and open offer. The primary use of the funds is to launch Accrufer® in the USA.

Shield is a de-risked, specialty pharmaceutical company focused on commercializing its lead product, Feraccru®/Accrufer®, a novel, non-salt-based oral therapy for adults with iron deficiency with or without anemia.

Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as the joint broker on this transaction.

Service

Funding, debt advisory & ECM

Parties

Talk to the deal team

Geoff Nash

Director

London, United Kingdom
Oaklins Cavendish

View profile Get in touch

Related deals

AMC Media Group has been acquired by Formedics

Healthcare | TMT

AMC Media Group has been acquired by Formedics

AMC Media Group, a health care professional (HCP) community platform that enables medical associations and key opinion leaders (KOLs) to drive engagement and monetization through their specialty digital properties, has been acquired by Formedics, an HCP community and engagement platform that is home to Physician's Weekly and OncWeekly.

Learn more

Bellefleur has been acquired by Domidep

Healthcare

Bellefleur has been acquired by Domidep

Belgian nursing home Bellefleur has been sold to Domidep, one of France’s largest private nursing home operators.

Learn more

Unitary Healthcare has been acquired by Axel Health

Private Equity | Healthcare | TMT

Unitary Healthcare has been acquired by Axel Health

Axel Health Oy, headquartered in Finland, has acquired the Finnish software company Unitary Healthcare Oy.

Learn more